(IN BRIEF) Evotec SE announced it has received a US$ 25 million payment from Bristol Myers Squibb, marking progress in their joint neuroscience partnership focused on neurodegenerative diseases. The milestone payment will further advance the companies’ preclinical pipeline and research … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged biotechnology, BMS-986419, Bristol-Myers Squibb, clinical trials, Cord Dohrmann, disease-modifying therapies, drug discovery, Evotec and Bristol Myers Squibb Advance Neuroscience Collaboration with New Funding Milestone, Evotec SE, EVT8683, milestone payment, neurodegenerative diseases, neuroscience, neuroscience collaboration, neuroscience research, pharmaceutical innovation, preclinical research, strategic partnership, translational medicine
(IN BRIEF) Evotec SE has announced that Esperion Therapeutics has nominated an oral preclinical development candidate for primary sclerosing cholangitis (PSC), marking a major milestone in their collaboration. The PDC, developed through Evotec’s integrated small molecule discovery platform and Esperion’s … Read the full press release
Posted in Business, Germany, Government, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged ACLY biology, bile ducts, clinical development, collaboration, Cord Dohrmann, drug discovery, Esperion Therapeutics, Evotec Advances Collaboration with Esperion as New ACLY-Based Candidate Targets Primary Sclerosing Cholangitis, Evotec and Esperion Advance Novel Treatment Candidate for Primary Sclerosing Cholangitis, Evotec INDiGO, Evotec SE, fibrosis, Frankfurt Stock Exchange EVT, hepatology, IND-enabling platform, liver disease, milestone payment, NASDAQ ESPR, NASDAQ EVO, preclinical development candidate, primary sclerosing cholangitis, PSC, rare diseases
(IN BRIEF) Basilea Pharmaceutica has received a CHF 1.7 million milestone payment from its partner Asahi Kasei Pharma following continued strong sales of Cresemba® in Japan—marking the second consecutive quarterly milestone. Cresemba, now marketed in over 70 countries, achieved USD … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AKP, antifungal treatment, Asahi Kasei Pharma, aspergillosis, azole antifungal, Basilea Pharmaceutica, biopharmaceuticals, branded antifungal leader, Cresemba®, cryptococcosis, David Veitch, fungal infection therapies, global antifungal sales, intravenous antifungal, invasive fungal infections, Isavuconazole, Japan pharmaceutical market, Japanese drug market, milestone payment, mucormycosis, oral antifungal, partnership
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?